Please assess the completion status of the following clinical trial:

Trial Title: PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate \>22 per minute).~2. Nasopharyngeal RT-PCR positive SARS-CoV-2~3. Age 20-50 years~4. BMI 18-28 kg/m2~5. Informed consent~Exclusion Criteria:~1. O2 saturation by pulse-oximeter below 93%~2. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes~3. Arrhythmias and/or history of arrythmia~4. Psoriasis and/or history of psoriasis~5. Neuropathy or myopathy and/or history of these~6. Hypoglycemia and/or history of hypoglycemia~7. Pre-existing hepatic disease~8. Pre-existing renal disease~9. Use of antacids within 1 week~10. Use of antiobiotics within 1 week~11. Pregnancy~12. RT-PCR performed \>7 days prior to enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- HCQ Regular dose (Type: ACTIVE_COMPARATOR): Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
- HCQ Loading dose (Type: EXPERIMENTAL): Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
- CQ regular dose (Type: ACTIVE_COMPARATOR): Cholorquine 500 mg BID for 5 days plus standard of care
- Placebo (Type: PLACEBO_COMPARATOR): Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)

Based on this trial design, predict the completion outcome and termination type (if applicable).